Dianthus Therapeutics, Inc. /DE/ Deferred Offering Costs
Dianthus Therapeutics, Inc. /DE/ (DNTH) had Deferred Offering Costs of $195.00 thousand as of 2019-03-31, per its 10-Q filed 2019-05-09.
Discontinued › Balance Sheet › Assets › Assets, Current
us-gaap:DeferredOfferingCosts · last filed 2019-05-09
- 2019-03-31: Deferred Offering Costs $195.00K.
- 2018-12-31: Deferred Offering Costs $0.00.
| Period end | Deferred Offering Costs |
|---|---|
| 2019-03-31 | $195.00K 10-Q · filed 2019-05-09 |
| 2018-12-31 | $0.00 10-Q · filed 2019-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |